Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany
Cortisol synthesis inhibitor osilodrostat (Isturisa®) is now available in Germany as of July 15, 2020, as a promising new therapy option for medical treatment of adult patients with endogenous Cushing’s syndrome (CS).1,4 Isturisa® was approved by the European Commission on January 9, 2020.
The approval of Isturisa® (osilodrostat) is based on the results of the pivotal phase III study, LINC-3, in which the efficacy and safety of osilodrostat in 137 patients with Cushing’s disease were assessed. A significantly higher proportion of patients with Cushing’s disease treated with Isturisa® maintained normal mean urinary free cortisol (mUFC) at the end of the 8‐week randomized withdrawal period (week 34) versus placebo (86% vs 29%). Cortisol level control is the primary objective in the treatment of patients with Cushing’s disease. Thus, the study successfully met its primary and key secondary endpoint.1,3 Moreover, the results showed that osilodrostat resulted in a rapid and sustained reduction of mean free urine cortisol levels maintained during the 48-week follow-up period. This was accompanied by improvements in clinical symptoms, comorbidity and quality of life.
"Data from the LINC-3 study underline the efficacy and safety of Isturisa® in a prospective setting and represent a significant advance in the treatment of patients with Cushing’s disease, a serious and potentially life-threatening rare disease," commented Pr. Rosario Pivonello, Professor of Endocrinology at the Federico II University of Naples (Italy). "I would like to thank all patients who participated in the LINC-3 study and their families who helped make this new and welcome therapy option available for this underserved patient population."
The launch of Isturisa® is an addition to the Recordati Rare Diseases endocrinology portfolio which also includes Signifor®, subcutaneous and intramuscular formulations, available across Europe, indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed, and for adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.5
High Burden of Disease and Impairment of Quality of Life
Cushing’s disease, the most common form of endogenous CS, is associated with high morbidity and burden of disease.2 As a result, those affected suffer from considerable impairments in their quality of life. In addition, the disease is associated with a large number of significant concomitant diseases as a result of the excessively elevated cortisol levels.2 These include metabolic syndrome, sleep disorders, osteoporosis, increased susceptibility to infections and/or neuropsychiatric disorders such as depression and anxiety.2 The mortality rate is correspondingly higher, in particular due to cardio-vascular complications. Without proper intervention to normalise cortisol levels, the mortality risk in patients with Cushing’s disease is up to five times higher than in the general population.2 Besides, there are indications that negative physical and psychosocial consequences of chronic hypercortisolism can persist a long time after remission.2 Because of these potentially life-threatening risks, rapid diagnosis and treatment are necessary.2,6
Multidisciplinary Treatment with a Need for Optimization
CS or Cushing’s disease require experienced multidisciplinary teams and individual treatment.2,7 Therapy goals are normalization of cortisol levels, improvement of clinical symptoms and quality of life as well as reduction of comorbidity-related risks.8,9
The primary treatment for Cushing’s disease is the surgical resection of the pituitary tumor. However, about a third of the patients do not achieve remission or present with long-term recurrences and, therefore, they require further therapy. Possible therapeutic options are repeat surgery, radiotherapy, bilateral adrenalectomy or medical treatments. The latter act either centrally on the pituitary gland or peripherally on the adrenal gland by inhibiting steroid synthesis. They are also used to bridge the gap between diagnosis of the disease and surgery or radiotherapy or its onset of action, or when surgical treatment is not an option.2,6,8,9
However, these medical treatments can only be used to a limited extent and/or can be associated with serious disadvantages and risks. For example, up to 50% of patients with Cushing's syndrome fail to reach normal cortisol levels with the currently available medical treatments, which in up to 28% of cases leads to dose adjustment or therapy discontinuation. Thus, there is an unmet need for more effective pharmacological interventions.2,8,9
The introduction of osilodrostat has thus opened up new therapeutic options. The data from prospective studies with a well-planned design indicate that this active ingredient is a promising, effective therapy option which is well tolerated.3,4
About Cushing’s Syndrome
Cushing's syndrome (CS) is caused by inappropriate and chronic exposure to excessive cortisol levels. The source of this excessive cortisol can be endogenous or exogenous (ie medication). Endogenous CS is most commonly caused either by an adrenal gland tumor (approx. 15%), leading to an excessive cortisol secretion, or by a pituitary adenoma (ie a tumor of the pituitary gland located in the brain) secreting excessive adrenocorticotropic hormone (ACTH), which accounts for about 70% of cases. Remaining 15% of cases are of other (ectopic) origin.2,10,11 With a prevalence of 40 cases per million inhabitants and an incidence of 1.2 to 2.4 per million per year Cushing’s disease is a rare disease.2,11 Women are affected about three times more often than men.2,7 The peak age is between the 4th and 6th decade of life.11 The disease is characterized by various long-term effects of glucocorticoids on organs and tissues and can, therefore, be very heterogeneous. Clinical symptoms include stretch marks on the skin (striae rubrae), obesity, muscle atrophy of the extremities, moon-shaped face, general weakness, osteoporosis, glucose intolerance, arterial hypertension, wound healing disorders, increased bleeding tendency and thromboembolic complications. However, many symptoms are non-specific and also appear in common diseases such as alcohol addiction, obesity or (poorly controlled) diabetes mellitus. Because of the low specificity of symptoms CS is often diagnosed late in the course of disease.6,10
Chronically elevated cortisol levels can lead to serious complications and comorbidities, severe impairment of quality of life and increased mortality.2,6 Therefore, normalizing cortisol levels is the main therapeutic goal.8,9 For most forms of CS surgical resection of the causative tumor is the primary treatment option. In case of a residual tumor or relapse irradiation is possible. However, symptoms decrease with a delay of several months to years. Medical treatments are used to bridge the gap between the diagnosis of the disease and surgery or until radiotherapy begins to work, as well as when there is no remission due to these procedures. A distinction is made between steroid synthesis inhibitors, which primarily act on adrenal gland, and substances, acting centrally on pituitary gland.6,8
LINC-3 is a prospective 48-week, phase III, multi-center study to evaluate the safety and efficacy of Isturisa® in patients (N = 137) with persistent or recurrent Cushing’s disease or with De Novo disease, who are not eligible for surgical therapy. The study consisted of a 12-week open-label dose titration period, followed by a 12-week maintenant period and an 8-week double-blind, randomized withdrawal phase in which eligible patients were randomized to receive 1: 1 osilodrostat or placebo, followed by another 14-week open-label phase with osilodrostat. The primary endpoint was the proportion of randomized patients who maintained complete response (mUFC ≤ULN with no dose increase above the level at week 26) at the end of the 8-week randomized withdrawal period (week 34). The key secondary endpoint was the proportion of patients with normal mUFC at week 24 and with no dose increase above the level established at week 12.1,3
The primary study endpoint was reached: significantly more patients in the osilodrostat group maintained a normal mUFC value without dose increase than in the placebo group (86% vs. 29%; p < 0.001) at the end of the 8-week randomized phase (week 34). More than half of the patients (53%) reached the key secondary endpoint of a normal mUFC value after the first 24 weeks of open therapy with osilodrostat, without increasing the dose after week 12. Two thirds (66%) of the patients had a normal mUFC at the end of the 48-week study. The reduction in cortisol levels was accompanied by improvements in cardiovascular and metabolic parameters (body weight, waist size, HbA1c, blood pressure). At week 48, 86% of the patients for whom data were available showed improvement in at least one physical characteristic of M. Cushing.1,3
Osilodrostat was well tolerated.3 The most commonly observed side effects in LINC-3 were nausea (42%), headache (34%), fatigue (44%) and adrenal insufficiency (51%).1
Isturisa® is a potent inhibitor of 11β-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol synthesis in the adrenal gland. Isturisa® is taken twice daily and is available as 1 mg, 5 mg and 10 mg film-coated tablets. Please see the prescribing information for detailed recommendations for the use of this product.1
About Recordati Rare Diseases
The company’s EMEA-headquarters is located in Puteaux, France, and its global headquarters is based in Milan, Italy.
For a complete list of products, visit www.recordatirarediseases.com/products.
You can find more information on our website at www.recordati.com and https://www.recordatirarediseases.com/ or follow us on LinkedIn or Twitter for the latest company news.
About Recordati Group
Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.
1 Isturisa® Fachinformation, Mai 2020
2 Pivonello R et al. Endocrine 2017; 56: 10–18
3 Biller BMK et al. Journal of the Endocrine Society2019; 3 (Supplement 1): OR16-2
4 Ferriere A, Tabarin A. Best Pract Res Clin Endocrinol Metab 2020; 34 (2): 101381
5 Signifor® and Signifor® LAR Fachinformation, Juni 2018
6 Petersen S. Diagnostik und Therapie des Cushing-Syndroms. In: Endokrinologie Informationen; Sonderheft März 2017: 38-43
7 Lacroix A et al. Lancet 2015; 386: 913
8 Nieman LK et al. J Clin Endocrinol Metab2015; 100: 2807
9 Broersen LHA et al. Pituitary 2018; 21: 631
10 Nieman LK et al. Am J Med 2005; 118: 1340–1346
11 Pivonello R et al. Endocrine Reviews 2015; 36: 385–486
For additional information:
Franchise Head Endocrinology - Germany
Tel.: +49 1522 8897110
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Opens New Dubai Taste Creative Center22.10.2020 22:15:00 CEST | Press release
Regulatory News: IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition & ingredients, today announced the opening of a new creation, application and innovation center for its Taste division in Dubai, UAE to better serve its customers’ unique needs and drive growth in the African, Middle Eastern, Turkish and Indian markets. “The new facility is a testament to our commitment to investing in the region and to support the specific innovation needs of our customers, leveraging dedicated leadership and cross-functional regional resources,” said Kathy Fortmann, Divisional CEO, Taste. “It will support our ongoing strategy to expand our geographic and customer reach, while accelerating growth in fast-growing emerging markets.” The state-of-the-art 1400m2 creative facility, centrally located in Dubai Science Park, will service companies in key regional markets by offering innovative flavors, savory solutions, juice-based compounds, inclusions, color
Saudi Arabia and International Telecommunication Union Announce MoU to Support AI for Sustainable Development Efforts22.10.2020 21:11:00 CEST | Press release
Saudi Arabia, represented by the Saudi Data and AI Authority (SDAIA), and the International Telecommunication Union (ITU) today announced a memorandum of understanding (MoU) to collaborate on initiatives aimed at supporting and strengthening efforts to optimize the benefits of AI technologies and applications for sustainable development. Under the partnership, Saudi Arabia will support ITU in developing projects, activities and initiatives that will, among other things, aim to facilitate greater multi-stakeholder participation, international cooperation, and knowledge sharing to accelerate progress towards the UN Sustainable Development Goals (SDGs). This could potentially include developing initiatives such as an “AI Readiness Landscape Framework” that would explore and highlight country responses, progress and best practices related to AI policy frameworks. The MoU was announced by HE Dr. Abdullah Bin Sharaf Alghamdi, President of SDAIA, and HE Houlin Zhao, Secretary-General of ITU,
Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies22.10.2020 19:57:00 CEST | Press release
Aerogen, the global leader in aerosol drug delivery, today announced details of a broad collaborative effort to support pharmaceutical companies from around the world as they work to develop COVID-19 vaccines and treatments. To date, more than ten million patients globally have been treated safely and effectively with Aerogen’s drug delivery technology 1,5–7. As the global scientific community rallies against the pandemic, there has been unprecedented interest in inhaled delivery of antiviral drugs, leading to Aerogen’s involvement in multiple COVID-19 drug development initiatives with leading pharmaceutical companies and prominent academic groups. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022006039/en/ Aerogen Ultra (Photo: Business Wire) Aerogen’s closed-circuit nebulizer technology, which addresses key concerns around safety and improves patient outcomes5–8, is being used in hospitals across the globe to deliver a
Five Highlights at the 26 th Yiwu Fair to Attract 50,000 Global Merchants22.10.2020 16:25:00 CEST | Press release
The 26th China Yiwu International Commodities (Standards) Fair ("Yiwu Fair") was opened on October 21 at Yiwu International Expo Center. The event, which will last till October 25, is expected to attract over 50,000 businessmen worldwide with these five highlights that can’t be missed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005798/en/ Highlight 1: Encouraging online and offline trade Due to the COVID-19 pandemic, exporters are facing great challenges this year. Therefore, Yiwu Fair 2020 invited more foreign business organizations and their representative offices in China. Around 10 delegations with 1,600 foreign businessmen in China are expected to attend. And online trade matchmaking meetings targeting Malaysia, the United Kingdom, Chile, etc. will allow exhibitors to connect with oversea traders online while meeting on-site foreign traders. Meanwhile, matchmaking meetings will also be held to help exhibitors
Hilton Effect Foundation Reveals 2020 Grants and Achieves $1 Million in Global COVID-19 Community Response Efforts22.10.2020 16:00:00 CEST | Press release
The Hilton Effect Foundation announced today its 2020 Hilton Effect grantees, which include community-based organizations playing a direct role in COVID-19 pandemic recovery efforts. Through these grants and donations already made by the Foundation, which serves as Hilton’s primary philanthropic arm, the Foundation has now awarded more than $1 million dollars in COVID-19 community response efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005724/en/ Hilton Effect Foundation reveals 2020 grants and achieves $1 million in global COVID-19 community response efforts. (Graphic: Hilton Effect Foundation) “A core part of the Hilton Effect Foundation’s work is to support our communities around the world through both good times and bad,” said Kate Mikesell, president, Hilton Effect Foundation. “From the very start of the pandemic, we have been listening to community leaders about the direct and indirect challenges they ar
Smiths Detection Inc. receives a $90.8M IDIQ contract to manufacture Joint Chemical Agent Detector Adapter for US Department of Defense22.10.2020 16:00:00 CEST | Press release
Smiths Detection Inc. (SDI), a global leader in threat detection and security screening technologies, announced it will initiate manufacturing of the Solid Liquid Adapter (SLA) following an indefinite delivery/indefinite quantity (IDIQ) award, worth potentially $90.8M over a maximum nine (9) year ordering period, with the US Department of Defense (DoD). The SLA adds new and expanded detection and identification capabilities to Joint Chemical Agent Detectors (JCAD), one of the DoD’s largest chemical detection programs in history. JCAD fitted with an SLA (JCAD SLA) gives the SLA operator the ability to both test for illicit drugs, including opioids such as fentanyl, and detect explosive compounds – without compromising the conventional chemical warfare agent detection capability of the JCAD. Speaking about the newly developed technology, Smiths Detection Inc. President, Shan Hood, said, “The SLA leverages existing technology, extending both capabilities and the life-cycle of widely deplo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom